Tenaya Therapeutics, a preclinical biotech developing multiple therapies to treat heart disease, filed on Friday with the SEC to raise up to $100 million.
The company's multi-modality drug discovery platform targets both genetic and non-genetic forms of heart disease, and consists of (1) a gene therapy program using AAVs, (2) a cellular regeneration program which also uses viral vectors to deliver gene combinations to regenerate cardiomyocytes in the heart, and (3) a precision medicine program using human induced pluripotent stem cell-derived cardiomyocytes. The company plans to submit INDs for its gene therapy and precision medicine platforms in 2022.
In addition to VC backers The Column Group and Casdin Capital, Tenaya's key shareholders include Walmart heir Thomas Walton.
The South San Francisco, CA-based company was founded in 2016 and plans to list on the Nasdaq under the symbol TNYA. Tenaya Therapeutics filed confidentially on May 7, 2021. Morgan Stanley, Cowen, and Piper Sandler are the joint bookrunners on the deal. No pricing terms were disclosed.
